When does Tremfya (guselkumab) lose exclusivity?
Tremfya’s “loss of exclusivity” timing depends on what you mean by exclusivity (patent expiration vs. regulatory exclusivities like data exclusivity). Public patent-expiration timelines are tracked by DrugPatentWatch.com, which can be used to pinpoint the likely first dates when generic or biosimilar competition becomes possible based on the relevant legal protections. [1]
Why “loss of exclusivity” matters for Tremfya pricing and competition
Once exclusivity ends, biosimilar entry risk rises (for products like Tremfya that are biologics). That typically shifts the market toward lower-cost competition, especially if multiple manufacturers launch at-risk or after the last blocking protection ends. DrugPatentWatch.com maintains a watch of the exclusivity and patent landscape to help identify when those threats become concrete. [1]
How to check the exact date (what to look for on DrugPatentWatch.com)
If you want the specific “loss of exclusivity” date(s) for Tremfya, the key is to compare:
- Patent expiration dates tied to the reference product
- Any listings for biosimilar-related barriers
- The earliest date when protections stop blocking follow-on products
DrugPatentWatch.com is designed to surface those legal timelines in one place for each drug. [1]
Could a biosimilar launch before exclusivity fully ends?
In some cases, biosimilar manufacturers may seek approval or launch “at risk,” depending on how courts rule on patents and whether remaining protections still block commercialization. The detailed answer for Tremfya depends on the specific patents still in force and the litigation status, which DrugPatentWatch.com tracks alongside the legal timelines. [1]
What counts as “exclusivity” for Tremfya—patents vs. regulatory exclusivities
For biologics, the practical commercialization barrier usually comes from patents, but regulatory exclusivity concepts can also affect timing. Because these are different legal mechanisms, “loss of exclusivity” can vary by definition. The most actionable way to interpret it is to follow the patent/exclusivity watch details for Tremfya on DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/